Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer

Mark D. Pegram, MD
Published Online: Thursday, Aug 10, 2017



Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab in combination with trastuzumab and chemotherapy in the first-line setting. That’s usually followed by ado-trastuzumab emtansine (T-DM1; Kadcyla) in the second-line setting, based on the pivotal EMILIA trial, explains Pegram.

Although EMILIA was not conducted in the pertuzumab metastatic breast cancer era, it is still assumed that T-DM1 will retain activity, states Pegram.
 


Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab in combination with trastuzumab and chemotherapy in the first-line setting. That’s usually followed by ado-trastuzumab emtansine (T-DM1; Kadcyla) in the second-line setting, based on the pivotal EMILIA trial, explains Pegram.

Although EMILIA was not conducted in the pertuzumab metastatic breast cancer era, it is still assumed that T-DM1 will retain activity, states Pegram.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x